Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)
112.10 x 4 112.15 x 8
Pre-market by (Cboe BZX)
111.09 -1.04 (-0.93%) 03/24/25 [NYSE]
112.10 x 4 112.15 x 8
Pre-market 111.91 +0.82 (+0.74%) 06:09 ET
Quote Overview for Mon, Mar 24th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
110.72
Day High
112.20
Open 111.94
Previous Close 112.13 112.13
Volume 1,543,400 1,543,400
Avg Vol 2,719,520 2,719,520
Stochastic %K 48.61% 48.61%
Weighted Alpha +13.03 +13.03
5-Day Change -1.13 (-1.01%) -1.13 (-1.01%)
52-Week Range 92.35 - 120.92 92.35 - 120.92
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 227,067,968
  • Shares Outstanding, K 2,044,000
  • Annual Sales, $ 51,722 M
  • Annual Income, $ 11,941 M
  • EBIT $ 14,544 M
  • EBITDA $ 20,658 M
  • 60-Month Beta 0.53
  • Price/Sales 4.55
  • Price/Cash Flow 10.58
  • Price/Book 5.24

Options Overview Details

View History
  • Implied Volatility 19.34% ( +0.31%)
  • Historical Volatility 21.46%
  • IV Percentile 51%
  • IV Rank 53.50%
  • IV High 25.21% on 04/19/24
  • IV Low 12.60% on 05/16/24
  • Put/Call Vol Ratio 4.64
  • Today's Volume 2,914
  • Volume Avg (30-Day) 5,427
  • Put/Call OI Ratio 1.03
  • Today's Open Interest 48,654
  • Open Int (30-Day) 59,950

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.07
  • Number of Estimates 4
  • High Estimate 2.24
  • Low Estimate 1.96
  • Prior Year 1.80
  • Growth Rate Est. (year over year) +15.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
107.51 +3.33%
on 02/27/25
Period Open: 109.22
116.91 -4.98%
on 03/10/25
+1.87 (+1.71%)
since 02/24/25
3-Month
96.91 +14.63%
on 01/02/25
Period Open: 98.35
116.91 -4.98%
on 03/10/25
+12.74 (+12.95%)
since 12/24/24
52-Week
92.35 +20.29%
on 04/18/24
Period Open: 96.23
120.92 -8.13%
on 08/30/24
+14.86 (+15.44%)
since 03/22/24

Most Recent Stories

More News
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains

The medical sector is one of the major adopters of artificial intelligence (AI), which is currently being used to synthesize new compounds for drugs and create devices for more precise measurement and...

ABT : 127.21 (+0.69%)
BSX : 102.67 (+1.97%)
LLY : 864.90 (+3.26%)
NVS : 111.09 (-0.93%)
MDT : 90.13 (-0.22%)
FDA Approves Novartis Drug for Rare Kidney Disease Treatment

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication.The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria.C3G...

BAYRY : 6.0500 (-7.07%)
NVS : 111.09 (-0.93%)
GILD : 106.74 (-0.32%)
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3...

AZN : 74.09 (-1.12%)
JNJ : 163.29 (-0.21%)
NVS : 111.09 (-0.93%)
PFE : 26.14 (-0.53%)
SNY : 55.93 (-1.70%)
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201.DR-0201 is...

NVS : 111.09 (-0.93%)
REGN : 661.00 (+0.38%)
PFE : 26.14 (-0.53%)
SNY : 55.93 (-1.70%)
The Best Vanguard ETF to Invest $1,000 in Right Now

What to invest in now -- that may seem like a tough decision, given the current economic uncertainty in the U.S. including ongoing tariff-related concerns. Investors are worried about inflation, about...

SONY : 25.27 (+0.16%)
SAP : 275.74 (+1.18%)
SPGI : 503.94 (+1.22%)
NVS : 111.09 (-0.93%)
RHHBY : 42.9100 (-1.81%)
VIGI : 84.62 (-0.07%)
NSRGY : 101.4700 (-2.01%)
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic...

ALNY : 290.70 (+2.60%)
NVS : 111.09 (-0.93%)
REGN : 661.00 (+0.38%)
RHHBY : 42.9100 (-1.81%)
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy?

After more than two years of a bull market run, the broader benchmark S&P 500 (SNPINDEX: ^GSPC) is starting to show some cracks. The index has given up all its post-election gains and finished Monday's...

SONY : 25.27 (+0.16%)
NVO : 75.33 (-1.99%)
$SPX : 5,767.57 (+1.76%)
RY : 115.91 (+2.03%)
NVS : 111.09 (-0.93%)
HSBC : 57.98 (+0.26%)
MUFG : 14.63 (-2.34%)
NSRGY : 101.4700 (-2.01%)
HTHIY : 25.1500 (-0.20%)
CBA.AX : 148.630 (+0.68%)
VYMI : 74.64 (+0.01%)
SHEL : 71.28 (+0.38%)
Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™

/CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) welcomes the Government of Alberta's decision to publicly reimburse Pluvicto™ (lutetium (177Lu)...

NVS : 111.09 (-0.93%)
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency has adopted a positive opinion for the label expansion of Fabhalta ((iptacopan).Fabhalta...

BMRN : 71.99 (+1.05%)
NVS : 111.09 (-0.93%)
GILD : 106.74 (-0.32%)
3 Dividend Stocks That Are No-Brainer Buys Right Now

It can be difficult to decide which dividend stocks to buy. After all, more than 5,700 of them trade on U.S. stock exchanges.

JNJ : 163.29 (-0.21%)
NVS : 111.09 (-0.93%)
PFE : 26.14 (-0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy,...

See More

Key Turning Points

3rd Resistance Point 113.43
2nd Resistance Point 112.82
1st Resistance Point 111.95
Last Price 111.09
1st Support Level 110.47
2nd Support Level 109.86
3rd Support Level 108.99

See More

52-Week High 120.92
Last Price 111.09
Fibonacci 61.8% 110.01
Fibonacci 50% 106.63
Fibonacci 38.2% 103.26
52-Week Low 92.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals